AstraZeneca pours $135M into boosting biologics capacity in Sweden

Anna Brown

News Reporter

AstraZeneca is spending $135 million to expand a biologics facility in Sweden due to an increase in demand for its pre-filled syringe drug products, a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca pours $135M into boosting biologics capacity in Sweden

Anna Brown

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

SEC probe of Illumina’s Grail deal targets sales forecasts, sources say

Arbor Biotechnologies cuts early-stage discovery work, lays off staff

Post-Hoc: Big promises built Moderna. They might also be its undoing

After a huge IPO and acquisition, Zymergen caps off bankruptcy with $30M SEC penalty

FDA approves subcutaneous Ocrevus, broadening access to Roche and Genentech blockbuster

Doug Williams returns with a ‘FIT’ bet on CAR-Ts; Biogen appoints Mene Pangalos to board

As­traZeneca pours $135M in­to boost­ing bi­o­log­ics ca­pac­i­ty in Swe­den

News Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

AstraZeneca pours $135M into boosting biologics capacity in Sweden